medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2006, Number 5

<< Back Next >>

Rev Invest Clin 2006; 58 (5)

The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México

Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Ruiz-Delgado GJ, Navarro-Vázquez M, González-Carrillo ML

Language: English
References: 17
Page: 458-461
PDF size: 61.32 Kb.


ABSTRACT

A new mutation (V617F) affecting the JAK2 gene has been recently described as acquired in patients with myeloproliferative disorders and other myeloid malignancies. Using an amplification refractory mutation system, we investigated this mutation in 70 Mexican mestizo patients with hematological malignancies: 28 cases of acute lymphoblastic leukemia, 17 cases of Ph1-positive chronic myelogenous leukemia, 8 patients with acute myelogenous leukemia, 6 patients with chronic lymphocytic leukemia, 6 patients with polycythemia vera (PV), two patients with essential thrombocythemia (ET), one patient with hypereosinophilic syndrome one patient with primary myelofibrosis (MF) and one patient with chronic myelomonocytic leukemia. The mutation was identified in 4 of 6 patients with PV, in one of 2 patients with ET and in the patient with MF. Our data add to the observation that the JAK2 V617F mutation seems to be rather uncommon in myeloid malignancies other than the classic BCR/ABL negative MPD.


REFERENCES

  1. 1 Thompson JE. JAK protein kinase inhibitors. Drug News Perspect 2005; 18: 305-10.

  2. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960; 25: 85-109.

  3. Tefferi A, Gilliland G. The JAK2 V617F tyrosine kinase mutation in myeloproliferative disorders: Status report and immediate implication for disease classification and diagnosis. Mayo Clin Proc 2005; 80: 947-58.

  4. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signallig causes polycythemia vera. Nature 2005; 434: 1144-8.

  5. Ruiz-Argüelles GJ, McArthur JR. Leucemias agudas. En: Fundamentos de Hematología, 3rd. edition. Ruiz-Argüelles GJ (Ed.). México: Editorial Médica Panamericana; 2003, pp. 225-45.

  6. Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, Abadi I, Caeiro F, Alvarellos A, Alarcón-Segovia D. The GLADEL multinational Latin American prospective inception cohort of 1214 patients with systemic lupus erythematosus. Ethnic and disease heterogeneity among “Hispanics”. Medicine 2004; 83: 1-17.

  7. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-61.

  8. Labardini-Méndez J. Síndromes mieloproliferativos. En: Fundamentos de Hematología, 3rd. edition. Ruiz-Argüelles GJ (Ed.). México: Editorial Médica Panamericana; 2003, pp. 261-78.

  9. Ruiz-Argüelles GJ, López-Martínez B, Lobato-Mendizábal E, Ruiz-Delgado GJ. An addition to geographic hematology: Chronic myeloproliferative diseases are infrequent in Mexican Mestizos. Int J Hematol 2002; 75: 499-502.

  10. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-8.

  11. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes Núñez V, Gómez- Rangel JD, Ruiz-Delgado GJ. More on geographic hematology: The breakpoint cluster regions of the PML/RARa fusion gene in Mexican mestizo patients with promyelocytic leukemia are different from those in Caucasians. Leuk Lymphoma 2004; 45: 1365-8.

  12. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Ruiz-Delgado GJ. Frequencies of the breakpoint cluster region types of the BCR/ABL fusion gene in Mexican mestizo patients with chronic myelogenous leukemia. Rev Invest Clin 2004; 26: 609-14.

  13. Ruiz-Argüelles GJ. Promyelocytic leukemia in Mexican mestizos. Blood 1997; 89: 348-9.

  14. Scott LM, Campbell PJ, Baxter J, Todd T, Stephens P, Edkins S, Wooster R, Stratton MR Futreal PA, Green AR. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005; 106: 2920-1.

  15. Goldman JM. A unifying mutation in chronic myeloproliferative disorders. N Engl J Med 2005; 352: 1744-6.

  16. Mesa RA, Powell H, Lasho T, deWald GW, McClure R, Tefferi A. A longitudinal study of the JAK2 V617F mutation in myelofibrosis with myeloid metaplasia: Analysis at two time points. Haematologica 2006; 91: 415-6.

  17. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Nuñéz V, Ruiz-Delgado GJ, Rosilio C, Camoriano JK. Clearance of the Janus Kinase 2 (JAK2) V617F mutation after allogenic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasis. Am J Hematol 2006; 58(5): 458-61.




2020     |     www.medigraphic.com